Defining molecular risk in ALK(+) NSCLC

Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLC) have the best prognosis among metastatic pulmonary malignancies, with a median patient survival currently exceeding 5 years. While this is definitely a major therapeutic success for thoracic oncology, it may not be entirel...

Descripción completa

Detalles Bibliográficos
Autores principales: Christopoulos, Petros, Budczies, Jan, Kirchner, Martina, Dietz, Steffen, Sültmann, Holger, Thomas, Michael, Stenzinger, Albrecht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517105/
https://www.ncbi.nlm.nih.gov/pubmed/31139322
http://dx.doi.org/10.18632/oncotarget.26886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517105/
https://www.ncbi.nlm.nih.gov/pubmed/31139322
http://dx.doi.org/10.18632/oncotarget.26886

Ejemplares similares